Atea Pharmaceuticals (AVIR) Non-Current Assets (2019 - 2026)

Atea Pharmaceuticals' Non-Current Assets history runs 8 years deep, the most recent figure standing at $3.9 million for Q1 2026.

• In Q1 2026, Non-Current Assets fell 38.0% year-over-year to $3.9 million; the TTM figure through Mar 2026 stood at $20.9 million (up 25.83% YoY), while the FY2025 annual figure was $4.2 million, up 82.75% from the prior year.
• Non-Current Assets for Q1 2026 stood at $3.9 million, down from $4.2 million in the prior quarter.
• The five-year high for Non-Current Assets was $6.8 million in Q3 2025, with the low at $2.3 million in Q4 2024.
• The 5-year median for Non-Current Assets is $4.6 million (2022), against an average of $4.8 million.
• The sharpest annual moves came in 2022 and 2024: Non-Current Assets jumped 1083.23% in 2022, then slumped 48.75% in 2024.
• Atea Pharmaceuticals' Non-Current Assets stood at $5.8 million in 2022, then declined by 22.0% to $4.5 million in 2023, then plunged by 48.75% to $2.3 million in 2024, then surged by 82.75% to $4.2 million in 2025, then dropped by 8.23% to $3.9 million in 2026.
• Business Quant data shows AVIR's Non-Current Assets at $3.9 million in Q1 2026, $4.2 million in Q4 2025, and $6.8 million in Q3 2025.